arrow
R

Raphael Mohr

Charité
H指数:23
被引数:2,186

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multicenter Study of Bleeding- and Thromboembolic-Events with Durvalumab ± Tremelimumab versus Atezolizumab and Bevacizumab in Advanced HCC: A Retrospective Analysis

多中心研究:在晚期HCC中,度鲁特玛±曲美木单抗与阿替利珠单抗和贝伐珠单抗的出血和血栓栓塞事件比较:一项回顾性分析

2026-03-110
OAAI
Soluble Urokinase Plasminogen Activator Receptor is a prognostic biomarker in decompensated liver cirrhosis

可溶性尿激酶型纤溶酶原激活剂受体是失代偿期肝硬化的预后生物标志物

2025-11-110
OAAI
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

方案:粪菌移植在肝癌中克服阿替利珠单抗/贝伐珠单抗耐药的多中心、随机、安慰剂对照、双盲II期试验(FLORA试验)

2025-09-090
OAAI
Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS
2024-05-010
OAAI
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

一项开放标签,单臂II期试验的研究方案,该试验研究了三氟尿苷/替匹拉西联合伊立替康作为胆管癌 (TRITICC) 患者二线治疗的疗效和安全性

2023-05-223
OAAI
Single-cell RNA sequencing identifies a population of human liver-type ILC1s
2023-01-0117
OAAI
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
2022-11-0120
OA